首页/数据集/Mosaic BRAF fusions are a recurrent cause of congenital melanocytic naevi targetable by MEK inhibition

Mosaic BRAF fusions are a recurrent cause of congenital melanocytic naevi targetable by MEK inhibition

ChEBI2023-09-30 更新2026-07-12 收录

皮肤黑色素细胞痣遗传学

药物机制研究

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-MTAB-13182 数据链接链接失效反馈

官方服务：

资源简介：

Mosaic BRAF fusions are a recurrent cause of congenital melanocytic naevi targetable by MEK inhibition

应用场景：

创建时间：

2023-09-30

无义突变通读

药物机制研究

The drug molecule PTC124 (Ataluren) has been described as a read-through agent, capable of suppressing premature termination codons (PTCs) and restoring functional protein production from genes disrup

Figshare2016-01-18 更新100

The IC 50 of the inhibitory effect of tylophora alkaloids on NF-κB, AP-1, and CRE signalging pathways in HepG2 and HEK-293 cells.

信号通路抑制

药物机制研究

Values are means ± SD of at least three experiments, with each data point done in triplicate. The IC50 concentrations of these compounds are significantly different (p<0.05) from each other in between

NIAID Data Ecosystem40

DataSheet5_Combined metabolomics and network pharmacology to elucidate the mechanisms of Dracorhodin Perchlorate in treating diabetic foot ulcer rats.xlsx

药物机制研究

糖尿病足溃疡治疗

Background: Diabetic foot ulcer (DFU) is a severe chronic complication of diabetes, that can result in disability or death. Dracorhodin Perchlorate (DP) is effective for treating DFU, but the potentia

NIAID Data Ecosystem30

CDK4/6 inhibitors induce repication stress to cause long-term cell cycle withdrawal

细胞周期调控

药物机制研究

CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are licenced to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate these efforts

NIAID Data Ecosystem60

Effect of SRPK1 inhibitor in ENKTL cells

淋巴瘤靶向治疗

药物机制研究

To explore the effect of SRPK1 inhibitor in ENKTL cells

NIAID Data Ecosystem40